Skip to content

Minerva Neurosciences to advance schizophrenia med to late stage trial

May 15, 2017

Minerva Neurosciences Inc. NERV, +7.14% shares rose 6.7% in premarket trade Monday after the company said its schizophrenia drug is expected to start late-stage clinical trials in the second half of this year. The drug, MIN-101, is intended to treat symptoms of the disease that affect an individual’s psychosocial functioning, such as decreased motivation, lack of initiative and restricted personal interaction, which are “one of the main sources of burden of illness,” the company said. These symptoms persist and worsen over the course of schizophrenia patients’ lives, said Minerva Neurosciences President and Chief Executive Remy Luthringer, and no drugs are currently approved to treat them. The phase 3 trial is expected to enroll about 500 patients in Europe and the U.S., and will be designed similarly to the phase 2b trial done last year. Minerva also plans phase 4 development of the drug to expand MIN-101’s patient profile, which could include comparing the rate of psychosis relapses to other drugs, or studying the drug in adolescents at high risk for schizophrenia, the company said. Minerva shares have declined 25.4% over the last three months, compared with a 1.8% rise in the S&P 500 SPX, -0.15%

http://on.mktw.net/2qnjbqk

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: